Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis
Mälkönen, Tarja; Nuutinen, Pauliina; Hallinen, Taru; Soini, Erkki; Nissinen, Riikka; Wennerstöm, Christina; Rantanen, Tapio; Hagman, Johanna H.; Harvima, Rauno; Höök-Nikanne, Johanna; Ilves, Tiina; Lintu, Päivi; Malanin, Ken; Soramäki, Iina; Tasanen, Kaisa; Teho, Arja; Vähävihu, Katja; Itälinna, Sari; Leinonen, Pekka; Sarajärvi, Piia; Huilaja, Laura; Pasternack, Rafael (2022-01-18)
Mälkönen, T., Nuutinen, P., Hallinen, T., Soini, E., Nissinen, R., Wennerstöm, C., Rantanen, T., Hagman, J. H., Harvima, R., Höök-Nikanne, J., Ilves, T., Lintu, P., Malanin, K., Soramäki, I., Tasanen, K., Teho, A., Vähävihu, K., Itälinna, S., Leinonen, P., Sarajärvi, P., Huilaja, L., & Pasternack, R. (2022). Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Dermato-Venereologica, 102, adv00631. https://doi.org/10.2340/actadv.v101.910
Copyright (c) 2021 Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
https://creativecommons.org/licenses/by-nc/4.0/
https://urn.fi/URN:NBN:fi-fe2022051836667
Tiivistelmä
Abstract
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.
Kokoelmat
- Avoin saatavuus [31657]